Arcadia Current Deferred Revenue vs Accounts Payable Analysis

RKDA Stock

USD 3.06 0.01 0.33%

Arcadia Biosciences financial indicator trend analysis is way more than just evaluating Arcadia Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcadia Biosciences is a good investment. Please check the relationship between Arcadia Biosciences Current Deferred Revenue and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

Current Deferred Revenue vs Accounts Payable

Current Deferred Revenue vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcadia Biosciences Current Deferred Revenue account and Accounts Payable. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Arcadia Biosciences' Current Deferred Revenue and Accounts Payable is -0.61. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Arcadia Biosciences, assuming nothing else is changed. The correlation between historical values of Arcadia Biosciences' Current Deferred Revenue and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Arcadia Biosciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Current Deferred Revenue i.e., Arcadia Biosciences' Current Deferred Revenue and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.61

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Accounts Payable

An accounting item on the balance sheet that represents Arcadia Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Arcadia Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Arcadia Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcadia Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.At present, Arcadia Biosciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 11.4 M, whereas Selling General Administrative is forecasted to decline to about 14.7 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	26.8M	19.6M	15.9M	21.7M
Cost Of Revenue	8.7M	9.8M	3.3M	3.1M

Total Operating Expenses Cost Of Revenue

Arcadia Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Liab	Other Assets	Long Term Debt
Total Assets		0.54	-0.44	-0.15	0.88	0.29	-0.27	0.03	-0.28	0.52	0.51	0.72	0.11	0.93	-0.19	0.03	0.5	0.21	0.62	0.42	0.43	0.26	0.97	-0.14	0.04	0.49
Short Long Term Debt Total	0.54		0.07	0.18	0.15	-0.19	0.53	0.72	0.53	-0.13	0.0	0.53	0.14	0.58	-0.02	-0.51	0.9	-0.41	-0.17	-0.4	0.91	-0.3	0.48	-0.25	0.38	0.94
Other Current Liab	-0.44	0.07		0.59	-0.69	-0.27	0.3	0.41	0.34	-0.76	-0.5	-0.4	0.05	-0.34	0.04	-0.23	0.19	-0.38	-0.58	-0.45	0.34	-0.28	-0.4	0.56	0.12	-0.01
Total Current Liabilities	-0.15	0.18	0.59		-0.34	0.17	0.04	0.07	0.16	-0.07	0.1	0.05	0.6	-0.18	0.36	-0.16	0.05	0.04	-0.46	-0.2	0.31	0.12	-0.2	0.08	0.56	-0.08
Total Stockholder Equity	0.88	0.15	-0.69	-0.34		0.4	-0.53	-0.36	-0.57	0.74	0.67	0.57	0.08	0.81	-0.17	0.27	0.08	0.45	0.84	0.73	-0.01	0.42	0.87	-0.27	-0.13	0.13
Property Plant And Equipment Net	0.29	-0.19	-0.27	0.17	0.4		-0.54	-0.37	-0.36	0.69	0.37	0.39	0.47	0.15	0.37	0.1	-0.15	0.86	0.42	0.45	-0.1	0.96	0.22	0.0	0.44	-0.35
Current Deferred Revenue	-0.27	0.53	0.3	0.04	-0.53	-0.54		0.6	0.9	-0.61	-0.33	0.06	-0.14	-0.21	0.31	-0.64	0.5	-0.66	-0.76	-0.89	0.49	-0.65	-0.34	-0.2	0.32	0.59
Net Debt	0.03	0.72	0.41	0.07	-0.36	-0.37	0.6		0.58	-0.62	-0.69	0.05	-0.01	0.1	-0.2	-0.38	0.72	-0.61	-0.37	-0.61	0.7	-0.39	0.02	0.03	0.17	0.73
Retained Earnings	-0.28	0.53	0.34	0.16	-0.57	-0.36	0.9	0.58		-0.48	-0.29	0.06	-0.1	-0.18	0.27	-0.83	0.59	-0.59	-0.79	-0.93	0.61	-0.53	-0.35	-0.03	0.5	0.54
Accounts Payable	0.52	-0.13	-0.76	-0.07	0.74	0.69	-0.61	-0.62	-0.48		0.76	0.48	0.25	0.42	0.1	0.16	-0.22	0.69	0.61	0.65	-0.22	0.64	0.47	-0.32	0.16	-0.24
Cash	0.51	0.0	-0.5	0.1	0.67	0.37	-0.33	-0.69	-0.29	0.76		0.5	0.18	0.44	0.3	0.05	-0.1	0.5	0.36	0.47	-0.07	0.3	0.46	-0.28	0.17	-0.08
Non Current Assets Total	0.72	0.53	-0.4	0.05	0.57	0.39	0.06	0.05	0.06	0.48	0.5		0.41	0.51	0.19	-0.1	0.46	0.23	0.16	0.08	0.45	0.35	0.52	-0.26	0.43	0.46
Non Currrent Assets Other	0.11	0.14	0.05	0.6	0.08	0.47	-0.14	-0.01	-0.1	0.25	0.18	0.41		-0.07	0.41	0.21	-0.11	0.36	-0.06	0.09	0.05	0.54	-0.01	-0.41	0.7	-0.07
Cash And Short Term Investments	0.93	0.58	-0.34	-0.18	0.81	0.15	-0.21	0.1	-0.18	0.42	0.44	0.51	-0.07		-0.32	-0.14	0.58	0.06	0.62	0.4	0.5	0.08	0.96	-0.08	-0.05	0.54
Net Receivables	-0.19	-0.02	0.04	0.36	-0.17	0.37	0.31	-0.2	0.27	0.1	0.3	0.19	0.41	-0.32		-0.21	-0.14	0.36	-0.38	-0.25	-0.04	0.26	-0.3	-0.39	0.64	-0.09
Common Stock Shares Outstanding	0.03	-0.51	-0.23	-0.16	0.27	0.1	-0.64	-0.38	-0.83	0.16	0.05	-0.1	0.21	-0.14	-0.21		-0.62	0.44	0.51	0.64	-0.65	0.36	0.06	-0.07	-0.49	-0.42
Non Current Liabilities Total	0.5	0.9	0.19	0.05	0.08	-0.15	0.5	0.72	0.59	-0.22	-0.1	0.46	-0.11	0.58	-0.14	-0.62		-0.41	-0.15	-0.44	0.96	-0.29	0.46	0.13	0.27	0.89
Inventory	0.21	-0.41	-0.38	0.04	0.45	0.86	-0.66	-0.61	-0.59	0.69	0.5	0.23	0.36	0.06	0.36	0.44	-0.41		0.56	0.63	-0.38	0.89	0.17	-0.09	0.16	-0.47
Other Current Assets	0.62	-0.17	-0.58	-0.46	0.84	0.42	-0.76	-0.37	-0.79	0.61	0.36	0.16	-0.06	0.62	-0.38	0.51	-0.15	0.56		0.9	-0.27	0.51	0.7	-0.07	-0.42	-0.13
Other Stockholder Equity	0.42	-0.4	-0.45	-0.2	0.73	0.45	-0.89	-0.61	-0.93	0.65	0.47	0.08	0.09	0.4	-0.25	0.64	-0.44	0.63	0.9		-0.47	0.58	0.49	-0.05	-0.4	-0.43
Total Liab	0.43	0.91	0.34	0.31	-0.01	-0.1	0.49	0.7	0.61	-0.22	-0.07	0.45	0.05	0.5	-0.04	-0.65	0.96	-0.38	-0.27	-0.47		-0.24	0.38	0.14	0.41	0.82
Property Plant And Equipment Gross	0.26	-0.3	-0.28	0.12	0.42	0.96	-0.65	-0.39	-0.53	0.64	0.3	0.35	0.54	0.08	0.26	0.36	-0.29	0.89	0.51	0.58	-0.24		0.19	-0.01	0.31	-0.43
Total Current Assets	0.97	0.48	-0.4	-0.2	0.87	0.22	-0.34	0.02	-0.35	0.47	0.46	0.52	-0.01	0.96	-0.3	0.06	0.46	0.17	0.7	0.49	0.38	0.19		-0.08	-0.1	0.44
Other Liab	-0.14	-0.25	0.56	0.08	-0.27	0.0	-0.2	0.03	-0.03	-0.32	-0.28	-0.26	-0.41	-0.08	-0.39	-0.07	0.13	-0.09	-0.07	-0.05	0.14	-0.01	-0.08		-0.31	-0.23
Other Assets	0.04	0.38	0.12	0.56	-0.13	0.44	0.32	0.17	0.5	0.16	0.17	0.43	0.7	-0.05	0.64	-0.49	0.27	0.16	-0.42	-0.4	0.41	0.31	-0.1	-0.31		0.17
Long Term Debt	0.49	0.94	-0.01	-0.08	0.13	-0.35	0.59	0.73	0.54	-0.24	-0.08	0.46	-0.07	0.54	-0.09	-0.42	0.89	-0.47	-0.13	-0.43	0.82	-0.43	0.44	-0.23	0.17

Click cells to compare fundamentals

Arcadia Biosciences Account Relationship Matchups

Arcadia Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Other Current Liab	4.5M	343K	264K	318K	1.9M	1.5M
Total Current Liabilities	5.7M	6.3M	5.0M	4.2M	3.6M	4.1M
Total Stockholder Equity	7.7M	27.7M	31.1M	21.0M	12.8M	14.6M
Property Plant And Equipment Net	3.8M	9.4M	5.4M	2.6M	1.2M	1.1M
Current Deferred Revenue	96K	42K	8K	64K	57.6K	54.7K
Net Debt	(6.2M)	(4.7M)	(25.4M)	(18.6M)	(5.5M)	(5.8M)
Retained Earnings	(207.2M)	(211.8M)	(226.5M)	(257.9M)	(271.8M)	(285.4M)
Accounts Payable	492K	4.1M	3.6M	2.9M	801K	761.0K
Cash	8.4M	14.0M	28.7M	20.6M	6.5M	6.2M
Non Current Assets Total	4.1M	15.7M	8.5M	3.5M	4.7M	5.5M
Non Currrent Assets Other	372K	5.5M	2.7M	932K	3.5M	2.5M
Cash And Short Term Investments	25.3M	25.7M	28.7M	20.6M	11.6M	11.1M
Net Receivables	602K	1.4M	1.4M	1.3M	514K	772.3K
Common Stock Shares Outstanding	159.1K	249.0K	532.0K	599.4K	1.2M	1.3M
Liabilities And Stockholders Equity	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Non Current Liabilities Total	18.5M	12.5M	7.7M	3.8M	3.4M	3.2M
Inventory	1.8M	3.8M	4.4M	2.6M	2.0M	1.6M
Other Current Assets	712K	811K	900K	809K	858K	720.2K
Other Stockholder Equity	214.8M	239.5M	257.5M	278.8M	284.5M	207.1M
Total Liab	24.2M	18.8M	12.7M	8.0M	7.0M	6.7M
Property Plant And Equipment Gross	3.8M	9.4M	5.4M	2.6M	3.7M	2.7M
Total Current Assets	28.4M	31.7M	35.4M	25.4M	15.0M	28.3M
Accumulated Other Comprehensive Income	(4.8M)	1K	0.0	101K	116.2K	122.0K
Other Liab	8.2M	16.9M	5.0M	5.5M	6.3M	8.1M
Other Assets	372K	5.5M	2.7M	1.0	0.9	0.86
Short Term Debt	635K	1.9M	1.1M	1.0M	852K	809.4K
Property Plant Equipment	1.1M	2.2M	9.4M	5.4M	6.2M	3.1M
Net Tangible Assets	12.8M	7.7M	26.9M	30.6M	35.2M	37.0M
Common Stock Total Equity	42K	45K	49K	54K	62.1K	51.0K
Retained Earnings Total Equity	(167.3M)	(178.4M)	(207.2M)	(211.8M)	(190.6M)	(200.2M)
Short Term Investments	9.8M	16.9M	11.6M	0.0	5.1M	4.9M
Capital Surpluse	175.2M	191.1M	214.8M	239.5M	275.4M	213.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:

How To Invest In Arcadia

Details

Is Arcadia Stock a good investment?

Details

What is Arcadia Biosciences' Net Worth?

Details

Largest Agricultural Products & Services Companies

View

Largest Food, Beverage & Tobacco Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

Note that the Arcadia Biosciences information on this page should be used as a complementary analysis to other Arcadia Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Arcadia Stock analysis

When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.

	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges

Is Arcadia Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(1.77)

Revenue Per Share

3.932

Quarterly Revenue Growth

(0.17)

Return On Assets

(0.34)

The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcadia Current Deferred Revenue vs Accounts Payable Analysis

Current Deferred Revenue vs Accounts Payable

Current Deferred Revenue vs Accounts Payable Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Accounts Payable

Arcadia Biosciences fundamental ratios Correlations

Arcadia Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcadia Biosciences fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Arcadia Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.97	Total Assets
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total
Long Term Debt	+ 0.94	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.93	Total Assets

Other Stockholder Equity	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.89	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Other Current Assets	- 0.79	Retained Earnings
Other Current Assets	- 0.76	Current Deferred Revenue
Accounts Payable	- 0.76	Other Current Liab